Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial
Study (n=50) found addition of venetoclax to intensive chemotherapy provided high rates of event free and overall survival at 12 months (68% & 85%) with 82% having undetectable measurable residual disease after induction. Febrile neutropenia was noted in 84% of patients.
Source:
The Lancet Haematology
SPS commentary:
A related editorial discusses this research and highlights various other studies which are investigating the use of venetoclax in different AML patient cohorts. It is currently licensed for use in AML in combination with a hypomethylating agent for newly diagnosed disease in those who are ineligible for intensive chemotherapy.